BeOne Medicines has been awarded an Innovation Passport for its investigational bispecific antibody BGB‑B2033, marking a significant step in the company’s plans to advance new treatment options for hepatocellular carcinoma. London‑based BeOne Medicines said the Medicines and Healthcare products Regulatory Agency granted the passport for BGB‑B2033, which targets GPC3 and 4‑1BB and is being developed for patients with advanced or metastatic hepatocellular carcinoma. James Harris, Interim General Manager, BeOne Medicines UK & Ireland Ltd., said: “Patients with hepatocellular carcinoma continue to face a poor prognosis, underscoring the urgent need for new treatment options. BGB‑B2033 is designed to target GPC3, a protein highly expressed in hepatocellular carcinoma, and 4‑1BB, an immune co‑stimulatory receptor. In the UK, around 7,000 people are diagnosed with liver cancer each year, with hepatocellular carcinoma accounting for 85% of cases.